News Releases

ALPN-101 demonstrates ability to potently inhibit both T and B cell responses in first-in-human study Human experience supports both IV and SQ dosing regimens SEATTLE --(BUSINESS WIRE)--Dec. 9, 2019-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused

SEATTLE --(BUSINESS WIRE)--Nov. 26, 2019-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced participation in an analyst-led fireside chat at

Company Advancing ALPN-101 into a Phase 1/2 Acute Graft versus Host Disease Study (BALANCE) Phase 1 Study (NEON-1) of Lead Oncology Program ALPN-202 Planned to Commence in Q1 2020 Conference Call Scheduled for 4:30 p.m. ET Today SEATTLE --(BUSINESS WIRE)--Nov.

ALPN-101 is distinct from the other biologic therapies and superior to combination biological blockade Preclinical activity suggests unique effectiveness across a range of rheumatic and other inflammatory diseases SEATTLE --(BUSINESS WIRE)--Nov. 12, 2019-- Alpine Immune Sciences, Inc.

  Preclinical data support unique mechanism of action of ALPN-202 as a first in class conditional CD28 Agonist ALPN-202 able to increase CD8+ T-cells in tumors ALPN-202 has potent monotherapy activity and significantly improves upon the activity of multiple anticancer therapies in preclinical

SEATTLE --(BUSINESS WIRE)--Nov. 6, 2019-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced an abstract has been accepted for an oral

Company to Discuss Topline Results and Provide Company Update on Third Quarter 2019 Conference Call and Webcast Scheduled for November 13, 2019 at 4:30 p.m. ET SEATTLE --(BUSINESS WIRE)--Oct. 30, 2019-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a clinical-stage immunotherapy company focused on

  SEATTLE --(BUSINESS WIRE)--Oct. 2, 2019-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced planned poster presentations at upcoming

SEATTLE --(BUSINESS WIRE)--Sep. 17, 2019-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced the company will present at the 2019 Ladenburg

ALPN-101 Progresses to Multiple-Ascending Dose Cohorts of Phase I Study ALPN-202 Submission for Clinical Trial Authorization Anticipated by Year End 2019 SEATTLE --(BUSINESS WIRE)--Aug. 13, 2019-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on